Your browser doesn't support javascript.
loading
Role and Limits of COVID-19 Vaccines in the Delicate Transition from Pandemic Mitigation to Endemic Control.
Mura, Marie; Simon, Fabrice; Pommier de Santi, Vincent; Tangy, Frédéric; Tournier, Jean-Nicolas.
Affiliation
  • Mura M; Microbiology and Infectious Diseases Department, Institut de Recherche Biomédicale des Armées (IRBA), 91220 Brétigny sur Orge, France.
  • Simon F; Innovative Vaccine Laboratory, Institut Pasteur, 75015 Paris, France.
  • Pommier de Santi V; Department of Infectious Diseases and Tropical Medicine, HIA Laveran, 13384 Marseille, France.
  • Tangy F; French Armed Forces Center for Epidemiology and Public Health (CESPA), 13014 Marseille, France.
  • Tournier JN; Innovative Vaccine Laboratory, Institut Pasteur, 75015 Paris, France.
Vaccines (Basel) ; 10(9)2022 Sep 18.
Article in En | MEDLINE | ID: mdl-36146633
ABSTRACT
The recent surge of COVID-19 related to the Omicron variant emergence has thrown a harsh light upon epidemic control in the near future. This should lead the scientific and medical community to question the long-term vaccine strategy for SARS-CoV-2 control. We provide here a critical point of view regarding the virological evolution, epidemiological aspects, and immunological drivers for COVID-19 control, including a vaccination strategy. Overall, we need more innovations in vaccine development to reduce the COVID-19 burden long term. The most adequate answer might be better cooperation between universities, biotech and pharmaceutical companies.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Vaccines (Basel) Year: 2022 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Vaccines (Basel) Year: 2022 Document type: Article Affiliation country: